BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 16549822)

  • 1. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors.
    Takeuchi T; Tomida S; Yatabe Y; Kosaka T; Osada H; Yanagisawa K; Mitsudomi T; Takahashi T
    J Clin Oncol; 2006 Apr; 24(11):1679-88. PubMed ID: 16549822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma.
    Iwakawa R; Kohno T; Anami Y; Noguchi M; Suzuki K; Matsuno Y; Mishima K; Nishikawa R; Tashiro F; Yokota J
    Clin Cancer Res; 2008 Jun; 14(12):3746-53. PubMed ID: 18559592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features.
    Shibata T; Uryu S; Kokubu A; Hosoda F; Ohki M; Sakiyama T; Matsuno Y; Tsuchiya R; Kanai Y; Kondo T; Imoto I; Inazawa J; Hirohashi S
    Clin Cancer Res; 2005 Sep; 11(17):6177-85. PubMed ID: 16144918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas.
    Matsuyama Y; Suzuki M; Arima C; Huang QM; Tomida S; Takeuchi T; Sugiyama R; Itoh Y; Yatabe Y; Goto H; Takahashi T
    Mol Carcinog; 2011 Apr; 50(4):301-9. PubMed ID: 21465578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
    Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
    Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations.
    Sakuma Y; Matsukuma S; Yoshihara M; Nakamura Y; Noda K; Nakayama H; Kameda Y; Tsuchiya E; Miyagi Y
    Am J Clin Pathol; 2007 Jul; 128(1):100-8. PubMed ID: 17580276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features.
    El-Zammar OA; Zhang S; Katzenstein AL
    Diagn Mol Pathol; 2009 Sep; 18(3):133-7. PubMed ID: 19704257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C; Holden JA; Layfield LJ
    Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers.
    Toyooka S; Tokumo M; Shigematsu H; Matsuo K; Asano H; Tomii K; Ichihara S; Suzuki M; Aoe M; Date H; Gazdar AF; Shimizu N
    Cancer Res; 2006 Feb; 66(3):1371-5. PubMed ID: 16452191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.
    Wu CC; Hsu HY; Liu HP; Chang JW; Chen YT; Hsieh WY; Hsieh JJ; Hsieh MS; Chen YR; Huang SF
    Cancer; 2008 Dec; 113(11):3199-208. PubMed ID: 18932251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
    Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
    Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis.
    Sartori G; Cavazza A; Bertolini F; Longo L; Marchioni A; Costantini M; Barbieri F; Migaldi M; Rossi G
    Am J Clin Pathol; 2008 Feb; 129(2):202-10. PubMed ID: 18208799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer.
    Yatabe Y; Takahashi T; Mitsudomi T
    Cancer Res; 2008 Apr; 68(7):2106-11. PubMed ID: 18381415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.
    Sartori G; Cavazza A; Sgambato A; Marchioni A; Barbieri F; Longo L; Bavieri M; Murer B; Meschiari E; Tamberi S; Cadioli A; Luppi F; Migaldi M; Rossi G
    Am J Clin Pathol; 2009 Apr; 131(4):478-89. PubMed ID: 19289583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts.
    Hayes DN; Monti S; Parmigiani G; Gilks CB; Naoki K; Bhattacharjee A; Socinski MA; Perou C; Meyerson M
    J Clin Oncol; 2006 Nov; 24(31):5079-90. PubMed ID: 17075127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor mutations in small cell lung cancer.
    Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
    Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ErbB3 mRNA expression correlated with specific clinicopathologic features of Japanese lung cancers.
    Kawano O; Sasaki H; Endo K; Suzuki E; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    J Surg Res; 2008 May; 146(1):43-8. PubMed ID: 17631905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type.
    Ninomiya H; Hiramatsu M; Inamura K; Nomura K; Okui M; Miyoshi T; Okumura S; Satoh Y; Nakagawa K; Nishio M; Horai T; Miyata S; Tsuchiya E; Fukayama M; Ishikawa Y
    Lung Cancer; 2009 Feb; 63(2):235-40. PubMed ID: 18571764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation.
    Cho WC; Chow AS; Au JS
    Eur J Cancer; 2009 Aug; 45(12):2197-206. PubMed ID: 19493678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.